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Pathogenic OPA1 mutations cause autosomal dominant optic atrophy (DOA), a condition characterized by
the preferential loss of retinal ganglion cells and progressive optic nerve degeneration. Approximately
20% of affected patients will also develop more severe neuromuscular complications, an important disease
subgroup known as DOA
1. Cytochrome c oxidase (COX)-negative ﬁbres and multiple mitochondrial DNA
(mtDNA) deletions have been identiﬁed in skeletal muscle biopsies from patients manifesting both the
pure and syndromal variants, raising the possibility that the accumulation of somatic mtDNA defects contrib-
ute to the disease process. In this study, we investigated the mtDNA changes induced by OPA1 mutations
in skeletal muscle biopsies from 15 patients with both pure DOA and DOA
1 phenotypes. We observed a
2- to 4-fold increase in mtDNA copy number at the single-ﬁbre level, and patients with DOA
1 features had
signiﬁcantly greater mtDNA proliferation in their COX-negative skeletal muscle ﬁbres compared with patients
with isolated optic neuropathy. Low levels of wild-type mtDNA molecules were present in COX-deﬁcient
muscle ﬁbres from both pure DOA and DOA
1 patients, implicating haplo-insufﬁciency as the mechanism
responsible for the biochemical defect. Our ﬁndings are consistent with the ‘maintenance of wild-type’
hypothesis, the secondary mtDNA deletions induced by OPA1 mutations triggering a compensatory mito-
chondrial proliferative response in order to maintain an optimal level of wild-type mtDNA genomes.
However, when deletion levels reach a critical level, further mitochondrial proliferation leads to replication
of the mutant species at the expense of wild-type mtDNA, resulting in the loss of respiratory chain COX
activity.
INTRODUCTION
Pathogenic mutations in the OPA1 gene (OMIM 605290)
account for  60% of all cases of autosomal dominant optic
atrophy (DOA), and the carrier rate in the general population
is estimated to be at least 1 in 50 000 (1). The majority of
patients are mono-symptomatic, with the onset of progressive
central visual loss in early childhood invariably resulting in sig-
niﬁcant visual morbidity (2–4). Although optic nerve dysfunc-
tion is the pathognomonic feature of DOA, we have recently
established that up to 20% of OPA1 carriers will experience a
more complicated disease course (5). These syndromal DOA
+
variants show a remarkable degree of phenotypic variability,
but sensorineural deafness is a frequent neurological deﬁcit,
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lowed by a combination of ataxia, myopathy, peripheral neuro-
pathy and progressive external ophthalmoplegia (PEO) from the
third decade of life onwards (5–9). These clinical observations
are of major pathophysiological importance, as they highlight
the deleterious consequences of OPA1 mutations not only for
retinal ganglion cells, whose axons constitute the optic nerve,
but also for other central neuronal populations, peripheral
nerves and skeletal muscle.
The marked inter- and intra-familial variability in disease
severity seen in DOA is likely to be a reﬂection of the mul-
tiple, distinct roles played by the Opa1 protein in normal cel-
lular function (10,11). Following proteolytic cleavage by
various proteases (12), Opa1 assembles as polymeric struc-
tures within the inner mitochondrial membrane. As a result
of its pro-fusion dynamin-like GTPase properties, Opa1
actively maintains a highly interconnected mitochondrial
network and sequesters pro-apoptotic cytochrome c molecules
within the mitochondrial cristae spaces (13,14). Opa1 is also
thought to regulate oxidative phosphorylation by stabilizing
the mitochondrial respiratory chain complexes and by facilitat-
ing the effective coupling of electron transport with ATP syn-
thesis (15,16). In addition to these essential biological
functions, there is now growing evidence supporting a novel
role for Opa1 in mitochondrial DNA (mtDNA) maintenance.
Central to this argument is the characteristic histochemical
ﬁnding of cytochrome c oxidase (COX)-negative ﬁbres in
skeletal muscle biopsies from OPA1-positive patients, together
with the presence of multiple mtDNA deletions on long-range
PCR analysis of homogenate skeletal muscle DNA (5–8).
Different mechanisms have been postulated to account for
the formation of these deleted mtDNA species, including an
imbalance of the intra-mitochondrial nucleotide pool, and
the impaired interaction of the N-terminal domain of Opa1
with mtDNA nucleoids, which are anchored in close physical
proximity to the inner mitochondrial membrane (6,7,17).
Interestingly, the level of COX-deﬁcient muscle ﬁbres was
found to be over four times higher in the DOA
+ group com-
pared with the pure optic atrophy group (5). Importantly,
COX-deﬁcient ﬁbres were also signiﬁcantly more frequent
among patients with pure DOA compared with age-matched
healthy controls (5). These observations strongly implicate a
contributory role for these secondary mtDNA defects in trig-
gering multi-system cellular dysfunction among affected
OPA1 carriers. However, the mechanisms involved have not
been deﬁned and the nature of the mtDNA deletions induced
by OPA1 mutations still remains to be clariﬁed. To explore
these fundamental research questions and how they relate to
disease severity, we performed a quantitative and qualitative
study of the mtDNA changes present in single skeletal
muscle ﬁbres from patients harbouring OPA1 mutations.
RESULTS
MtDNA copy number density varies in normal control
skeletal muscle ﬁbres
The normal control muscles studied were collected from a
1-year-old female (C-1F), a 22-year-old female (C-22F), a
31-year-old female (C-31F), a 35-year-old male (C-35M)
and a 52-year-old female (C-52F). The mtDNA copy
number density was measured as the total number of
mtDNA molecules in a muscle ﬁbre section, divided by the
ﬁbre’s cross-sectional area. There was a statistically signiﬁcant
variation in mtDNA copy number density among Type I skel-
etal muscle ﬁbres from the ﬁve controls, except for C-1F
versus C-22F (C-1F: mean ¼ 3.20, SD ¼ 1.67, n ¼ 18;
C-22F: mean ¼ 2.50, SD ¼ 0.87, n ¼24; C-31F: mean ¼
5.62, SD ¼ 1.97, n ¼19; C-35M: mean ¼ 10.63, SD ¼ 3.22,
n ¼17; C-52F: mean ¼ 4.36, SD ¼ 0.92, n ¼21) (Fig. 1A,
Supplementary Material, Table S1A). Similarly, mtDNA
copy number density varied signiﬁcantly among Type II skel-
etal muscle ﬁbres, except for C-1F versus C-31F, and C-1F
versus C-52F (C-1F: mean ¼ 2.62, SD ¼ 0.98, n ¼13;
C-22F: mean ¼ 1.57, SD ¼ 0.60, n ¼24; C-31F: mean ¼
2.96, SD ¼ 0.85, n ¼17; C-35M: mean ¼ 4.13, SD ¼ 1.54,
n ¼14; C-52F: mean ¼ 2.45, SD ¼ 0.50, n ¼22) (Fig. 1B,
Supplementary Material, Table S1B).
Figure 1. Total mtDNA content of single skeletal muscle ﬁbres from normal
controls: (A) Type I ﬁbres, (B) Type II ﬁbres.
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somatic mtDNA deletions in skeletal muscle ﬁbres
The mean frequency of COX-negative ﬁbres present in cryo-
stat muscle sections from 15 OPA1-positive patients was
4.49% (SD ¼ 7.00%, range ¼ 0–21.20%, n ¼15), with two
patients, H and J, not harbouring any COX-negative ﬁbres
(Table 1). The presence and level of mtDNA deletion were
determined for a total of 333 single skeletal muscle ﬁbres
from 15 patients: (i) Type I COX positive, n ¼ 94; (ii) Type
II COX positive, n ¼ 94; and (iii) COX-negative, n ¼ 145
(Table 2). The majority of COX-positive ﬁbres harboured
low deletion levels ,30% (179/188, 95.2%), and there was
no signiﬁcant difference in mean deletion levels between
Type I and II ﬁbres (Type I: mean ¼ 11.60%, SD ¼ 7.99%;
Type II: mean ¼ 14.58%, SD ¼ 11.51%, P ¼ 0.0723).
Among COX-negative ﬁbres, 113 of 145 (77.9%) had deletion
levels ≥70%, and the mean deletion level was signiﬁcantly
Table 1. Clinical phenotype and OPA1 mutational spectrum of our study cohort
Patient Age
(years)
Sex Onset
a
(years)
OPA1 mutation Clinical phenotype
cDNA AA change Optic atrophy Deafness Ataxia Myopathy Neuropathy PEO Others
A 31 M 11 c.876-878del p.V294fsX667 +
B 59 M 5 c.876-878del p.V294fsX667 ++ HSP
C 44 M 2 c.1198C.T p.P400S ++ +
D 54 M 5 c.1212+3a.t Splice defect ++
E 43 M 5 c.1334G.A p.R445H ++ + +
F 43 F 5 c.1334G.A p.R445H ++ + +
G 54 M – c.1516+1g.t Splice defect +
H 39 M 15 c.1516+1g.t Splice defect +
I 58 F – c.2613+1g.a Splice defect ++ MS-like illness
J 50 M 8 c.2613+1g.a Splice defect +
K 43 M 5 c.2708_2711del p.V903fsX3 +
L 60 F 16 c.2713C.T p.R905X +
M 40 F 15 c.2713C.T p.R905X +
N
b 60 M – c.768C.G p.S256R ++ + + Spasticity
c.854A.G p.Q285R
O
b 64 F – c.768C.G p.S256R ++ + + Spasticity
c.854A.G p.Q285R
AA, amino acid; F, female; HSP, hereditary spastic paraparesis; M, male; MS, multiple sclerosis; PEO, progressive external ophthalmoplegia.
aAge of onset of visual failure.
bNorwegian siblings compound heterozygous for two novel OPA1 mutations (5).
Table 2. Histochemical and mtDNA defects identiﬁed in skeletal muscle biopsies from our OPA1-positive patients
Patient Skeletal muscle biopsy analysis Real-time PCR analysis COX 2ve single-ﬁbre analysis
a
Fibres (n)
b COX 2ve (%) RRF (%) Long PCR
c Type I (n)
d Type II (n)
d COX 2ve (n) Deletion ,70% Deletion ≥70%
(n) (%) (n) (%)
A 2826 0.1 0.0 + 15 14 2 1 50.0 1 50.0
B 482 2.1 0.6 ++ 14 14 8 3 37.5 5 62.5
C 1980 1.6 0.6 ++ 14 22 12 3 25.0 9 75.0
D 786 0.3 0.0 + 24 23 2 1 50.0 1 50.0
E 1272 3.1 0.7 ++ 19 12 20 3 15.0 17 85.0
F 1186 13.9 1.3 ++ 13 21 13 2 15.4 11 84.6
G 674 1.8 0.9 ++ 19 17 16 7 43.8 9 56.3
H 762 0.0 0.0 + 19 23 0 N/A N/A N/A N/A
I 1304 1.4 0.3 ++ 21 21 15 1 6.7 14 93.3
J 848 0.0 0.0 – 14 19 0 N/A N/A N/A N/A
K 832 0.6 0.1 + 14 13 6 2 33.3 4 66.7
L 1100 3.0 0.8 ++ 10 10 14 3 21.4 11 78.6
M 1126 0.5 0.1 + 14 15 6 0 0.0 6 100.0
N 1058 17.7 3.3 ++ 22 17 16 4 25.0 12 75.0
O 968 21.2 5.8 ++ 15 28 15 2 13.3 13 86.7
COX, cytochrome c oxidase; MtDNA, mitochondrial DNA; N/A, not applicable; PCR, polymerase chain reaction; RRF, ragged-red ﬁbres.
aLevel of mtDNA deletion detected in single COX-negative muscle ﬁbres using our quantitative real-time PCR assay.
bTotal number of muscle ﬁbres present in the stained cryostat sections.
cLong PCRanalysis of homogenate skeletal muscleDNA: (i) no deletion bands(2), (ii) smaller deletion bands in additionto the wild-typePCR fragment(+), and
(iii) multiple deletion bands with no wild-type PCR fragment (++).
dNumber of Type I and II COX-positive muscle ﬁbres laser microdissected from 20 mm thick membrane sections.
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(mean ¼ 74.16%, SD ¼ 33.04%, P , 0.0001) (Fig. 2).
COX-negative but not COX-positive muscle ﬁbres are
associated with signiﬁcant mtDNA proliferation
There was no signiﬁcant difference in mtDNA copy number
density between COX-positive ﬁbres from OPA1-positive
patients and the combined control data set for both Type I
ﬁbres (OPA1:m e a n¼ 4.37, SD ¼ 2.23; controls: mean ¼ 4.91,
SD ¼ 3.17, P ¼ 0.0743), and Type II ﬁbres (OPA1:m e a n¼
2.39, SD ¼ 1.03; controls: mean ¼ 2.60, SD ¼ 1.20, P ¼
0.1095) (Fig. 3). However, there was evidence of signiﬁcant
mtDNA proliferation in COX-negative ﬁbres when compared
with adjacent COX-positive ﬁbres from the same patient
(Table 3, Supplementary Material, Fig. S1A–O), and COX-
positive ﬁbres from the combined control data set (Fig. 4).
There was no signiﬁcant difference in mean mtDNA copy
number density between COX-negative ﬁbres with mtDNA del-
etion levels ≥70% (mean ¼ 11.55, SD ¼ 8.83, n ¼113) and
,70% (mean ¼ 9.10, SD ¼ 5.32, n ¼32, P ¼ 0.1385). Of the
145 COX-negative ﬁbres analysed, 44 were from patients with
pure DOA (mean mtDNA proliferation ratio ¼ 2.02, SD ¼
1.31, 95% conﬁdence interval (CI) ¼ 1.63–2.42) and 141 were
from patients with DOA
+ phenotypes (mean mtDNA prolifer-
ation ratio ¼ 2.66, SD ¼ 1.52, 95%CI ¼ 2.36–2.96),the differ-
ence being statistically signiﬁcant (P ¼ 0.0172) (Fig. 5).
MtDNA proliferation in COX-negative muscle ﬁbres fails
to maintain normal levels of wild-type mtDNA molecules
The mean wild-type mtDNA ratio was signiﬁcantly lower for
the COX-negative group (mean ¼ 0.20, SD ¼ 0.19, 95% CI ¼
0.17–0.24, n ¼112) compared with the COX-positive group
(mean ¼ 1.00, SD ¼ 0.32, 95% CI ¼ 0.95–1.05, n ¼188,
P , 0.0001) (Fig. 6A). The relationship between the wild-type
mtDNA ratio and the deletion level for COX-negative muscle
ﬁbres was in agreement with our previously established
in silico model of mtDNA replication (R
2 ¼ 0.68), and gave
a predicted maximum mitochondrial proliferation factor (a)
of 3.40 (95% CI ¼ 2.60–4.80) (Fig. 6B).
COX-negative muscle ﬁbres from OPA1 patients harbour
clonally expanded deleted mtDNA species
Deleted mtDNA species were detected in 31 COX-negative
muscle ﬁbres using our two-step long-range PCR protocol,
and in none of them was the full-length 10 843 base pairs
PCR product obtained. MtDNA deletions levels ,30% were
measured in 6 of 31 (19.4%) of these COX-negative ﬁbres
with our differential MTND1–MTND4 real-time PCR assay.
The deletion sizes ranged from 1.0 to 8.0 kb (mean ¼ 5.2 kb,
SD ¼ 2.0 kb, n ¼33), and two different deletions were ampli-
ﬁed from the lysate of 2 of 31 (6.5%) COX-negative ﬁbres. All
these deletions were located within the major arc of the mito-
chondrial genome and they were predicted to result in the loss
of critical segments containing both transfer RNA and
protein-encoding genes.
DISCUSSION
Our study has revealed marked mtDNA proliferation in skel-
etal muscle from patients harbouring a range of pathogenic
OPA1 mutations. This observation is entirely compatible
with the reported detrimental effect of OPA1 mutations on
mitochondrial oxidative phosphorylation (15,16,18), with the
increased mtDNA copy number acting as a compensatory
mechanism to maintain an adequate level of ATP for normal
cellular function. COX-negative ﬁbres were present in
muscle biopsies from 13 OPA1-positive patients, and there
was a consistent ﬁnding of mtDNA proliferation in these
ﬁbres, irrespective of disease severity. However, patients
with DOA
+ phenotypes had signiﬁcantly higher proliferation
ratios in COX-negative muscle ﬁbres when compared with
those with isolated optic nerve involvement, indicating a poss-
ible important disease mechanism. Although we did not make
any direct measurements of apoptotic markers in this study,
mtDNA proliferation is linked with an increased susceptibility
to undergo apoptosis in mitochondrial myopathies (19,20), and
it is biologically plausible to postulate that such an effect
would not be limited to muscle ﬁbres, but would also extend
to other post-mitotic tissues commonly affected in mitochon-
drial disorders. The relevance to OPA1 disease becomes
even more apparent in view of the fact that the level of
COX deﬁciency in skeletal muscle is over four times higher
in patients with DOA
+ compared with pure DOA (5). Even
though the frequency of COX-negative ﬁbres is lower
among DOA patients with clinical features limited to the
Figure 2. Level of mtDNA deletion in COX-positive and COX-negative
single muscle ﬁbres from OPA1-positive patients. NS at P-value ¼ 0.0723;
∗∗∗P-value ,0.0001. Type I and Type II refer to COX positive ﬁbres.
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COX-deﬁciency compared with age-matched healthy controls
(5). The secondary mtDNA abnormalities, which precipitate
this biochemical COX defect are therefore clearly linked to
the underlying OPA1 disease process. Although additional
conﬁrmatory studies are required, it is tempting to speculate
that some OPA1 mutations lead to multi-systemic manifes-
tations and more severe visual failure as a result of their
more pronounced effects on mtDNA deletion formation, and
thus proliferation, with the consequent increase in apoptotic
cell loss. The degree of mitochondrial network instability
induced by different OPA1 mutations also deserves further
investigation, as the extent of fragmentation could have a
crucial inﬂuence on the rate at which these somatic deletions
become ﬁxed at supra-threshold levels (21–23).
Our in silico model of mtDNA replication suggests that
mitochondrial proliferation serves a useful biological
purpose by maintaining wild-type mtDNA copy number at
an optimal level (21,22). However, this compensatory mech-
anism only operates effectively up to a certain mutational
load, beyond which it fails to prevent the loss of wild-type
mtDNA genomes, and eventually becomes detrimental to
cellular survival. The relationship observed in COX-negative
OPA1 muscle ﬁbres between the level of wild-type and
deleted mtDNA species is in agreement with our in silico pre-
diction, and provides additional experimental evidence that the
maintenance of wild-type mtDNA genomes is crucial for
normal mitochondrial oxidative function. We previously
showed that this was also the case in skeletal muscle ﬁbres
from a patient with PEO and mild proximal myopathy due
to a 4.9 kb single deletion (23).
MtDNA copy number was determined at the single-ﬁbre
level for ﬁve normal control skeletal muscle samples, and a
wide variation was observed for both Type I and II ﬁbres. A
likely confounding variable is the level of physical activity,
which was not documented for the individuals from whom
the biopsies were taken. Skeletal muscle is a highly adaptable
tissue and it is capable of pronounced metabolic and morpho-
logical changes in response to endurance training or disuse
(24,25). It is well established that physical exercise enhances
mitochondrial oxidative capacity in vivo (26–28), and this
beneﬁcial adaptation has been linked to an increase in
mtDNA density (29,30). The regulatory pathways involved
are complex but an important element is the up-regulation in
the level of TFAM expression (31,32), which encodes for a
Figure 3. Comparison of total mtDNA copy number in single muscle ﬁbres from OPA1-positive patients with normal controls. (A) Type I COX-positive ﬁbres
(NS at P-value ¼ 0.0743), (B) Type II COX-positive ﬁbres (NS at P-value ¼ 0.1095). The control values represent the combined data set for C-1F, C-22F,
C-31F, C-35M, and C-52F.
Table 3. Relative level of mtDNA proliferation seen in COX-negative muscle
ﬁbres
Patient COX 2ve ﬁbres (n)
a MtDNA proliferation ratio
b
Mean 95% conﬁdenceinterval
A 2 2.68 0.00 16.28
B 8 2.32 1.45 3.18
C 12 1.92 1.28 2.56
D 2 2.49 0.00 16.14
E 20 3.72 2.94 4.49
F 13 2.21 1.36 3.06
G 16 1.90 1.31 2.50
H 0 N/A N/A N/A
I 15 2.76 2.07 3.44
J 0 N/A N/A N/A
K 6 3.11 1.23 4.98
L 14 1.75 1.07 2.44
M 6 1.68 0.34 3.02
N 16 3.24 2.25 4.22
O 15 1.73 1.26 2.21
aTotal number of COX-negative muscle ﬁbres studied for each patient.
bThe proliferation ratio for each COX-negative ﬁbre was determined in relation
to the mean mtDNA copy number (/mm
2) for COX-positive ﬁbres from the
same patient, with a value .1 indicating relative mtDNA proliferation
(Supplementary Material, Fig. S1A–O).
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Our ﬁnding therefore highlights the need for caution when
comparisons are made between individual patient muscle
biopsies and controls, as erroneous conclusions could easily
be reached, especially if only limited numbers are analysed.
For this reason, we combined Type I and II ﬁbres from our
control data set, and used this normative range to interpret
the results obtained from OPA1-positive muscle biopsies
included in this study.
The majority of COX-positive muscle ﬁbres from OPA1-
positive patients had sub-threshold deletion levels ,30%
(179/188, 95.2%), i.e. within the detection limit of our quan-
titative real-time PCR assay (23,35,36). The mtDNA deletion
level required to precipitate an overt biochemical defect at
the cellular level is typically ≥70% in skeletal muscle
(23,35,36), and using this threshold value, the histochemical
status for over three-quarters of COX-negative muscle ﬁbres
could be accounted for (113/145, 77.9%). By applying a
two-step long-range PCR strategy, clonal expansion of a
single deleted mtDNA species was demonstrated for 29 of
31 (93.5%) COX-negative ﬁbres, with the remaining ﬁbres
each harbouring two different deleted mtDNA species.
Although long-range PCR is not quantitative, these results
suggest that more than one deleted mtDNA species can pro-
pagate and reach high levels within a cell independently of
each other. We recently reported the same observation in
single substantia nigra neurones from three different
groups: controls, patients with sporadic Parkinson’s disease,
and a patient with a heterozygous POLG1 mutation leading
to parkinsonism in association with PEO and multiple
mtDNA deletions (37). It is also noteworthy that 6 of 31
(19.4%) COX-negative muscle ﬁbres had mtDNA deletions
levels ,30% with our real-time PCR assay, which was
designed primarily to detect deletions encompassing
MTND4 but not MTND1 (23,38). It is therefore likely that
Figure 4. Comparison of total mtDNA copy number in COX-negative muscle ﬁbres from OPA1-positive patients with COX-positive muscle ﬁbres from the
combined control data set. MtDNA deletion levels in COX-negative muscle ﬁbres: low (,70%) and high (≥70%); NS at P-value ¼ 0.1385; ∗∗∗P-value
,0.0001.
Figure 5. MtDNA proliferation ratio for COX-negative ﬁbres from patients
with pure DOA and DOA
+ phenotypes. The proliferation ratio for each COX-
negative ﬁbre was determined in relation to the mean mtDNA copy number
(/mm
2) for COX-positive ﬁbres from the same patient, with a value .1 indi-
cating relative mtDNA proliferation. ∗P-value ¼ 0.0172.
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(32/145, 22.1%) in our study actually harboured smaller del-
etions, which spared both MTND1 and MTND4, and there-
fore remained undetected. In support of this argument, Bua
et al.( 39) sequenced the breakpoints for 48 mtDNA del-
etions identiﬁed in aged normal skeletal muscle, and of
these, 8 of 48 (16.7%) did not include MTND1 and
MTND4. We have not excluded the possibility that OPA1
mutations could trigger COX deﬁciency via the accumulation
of high levels of somatic mtDNA point mutations, but the
evidence for this is weak, especially in post-mitotic tissues
(40,41). Furthermore, previous studies of other mitochondrial
maintenance disorders due to POLG1 and PEO1 mutations
have only identiﬁed an increased burden of somatic
mtDNA point mutations in the non-coding D-loop region
(42–44). The signiﬁcance of these mtDNA variants
remains unclear but they would not be predicted to directly
cause COX deﬁciency.
In summary, our study has provided some important
insights into the consequences of OPA1 mutations at the cel-
lular level and has revealed possible important disease mech-
anisms. The accumulation of somatic, clonally expanded
mtDNA deletions is a key pathological player, and the result-
ing mtDNA proliferation is likely to be an important mediator
of apoptotic cell loss and disease severity. However, several
intriguing features of OPA1 disease remain to be clariﬁed –
its wide phenotypic spectrum, the marked variability seen
within families segregating the same pathological variant,
and the greater susceptibility of retinal ganglion cells. Dissect-
ing the complex pathophysiological pathways involved will
represent a major challenge, and future experimental para-
digms will require the development of more sophisticated
functional systems, such as animal models replicating the fea-
tures seen in patients with DOA
+ phenotypes.
MATERIALS AND METHODS
Patients and controls
Quadriceps or tibialis anterior muscle biopsies from 15 OPA1-
positive patients (mean age ¼ 49.5 years, SD ¼ 9.8 years,
range ¼ 31.0–64.0 years) (Table 1), and ﬁve normal controls
with no evidence of ocular or neuromuscular pathologies
(mean age ¼ 28.2 years, SD ¼ 18.7 years, range ¼ 1.0–52.0
years) (Fig. 1) were included in this study. Among the DOA
group, seven patients had isolated optic nerve involvement
whereas eight patients manifested additional neuromuscular
features. The clinical descriptions of these patients have
been detailed previously (5), and muscle biopsies were
obtained at the time of their initial diagnostic investigations.
This study had the relevant institutional approval and com-
plied with the Declaration of Helsinki.
Mitochondrial histochemistry
Skeletal muscle samples were snap frozen in melting liquid
isopentane (21508C) within 6 h of the biopsy being taken
and then stored at 2808C. The specimens were mounted on
OCT (VWR BDH Prolabo, UK) before being sectioned at
20 mm thickness onto glass and membrane slides using a
MicromTM HM560 cryostat (Thermo Fisher, Germany). The
serial muscle sections were then stained for COX, succinate
dehydrogenase (SDH), and sequential COX-SDH activities,
using standard histochemical protocols (45).
Single-muscle ﬁbre analysis
Individual skeletal muscle ﬁbres were cut using an LMD
6000TM laser dissecting microscope (Leica Microsystems,
Germany) and collected into a 0.5 ml microcentrifuge cap
Figure 6. (A) Wild-type mtDNA ratio in single muscle ﬁbres from OPA1-positive patients analysed according to COX status (P , 0.0001), (B) Variation in
wild-type mtDNA ratio for COX-negative muscle ﬁbres according to mtDNA deletion level. The simulated curve describes the relationship predicted by our
in silico model, which is based upon the maintenance of wild-type mtDNA genomes (R
2 ¼ 0.68). Circles indicate COX-positive ﬁbres and triangles
COX-negative ﬁbres.
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2) was
recorded from the LMD 6000TM operating software (Leica
Microsystems) prior to laser microdissection. The ﬁbres
were incubated overnight in a 30 ml lysis solution containing
proteinase K at 558C for 16 h, followed by heat inactivation
at 958C for 10 min (23). The molecular investigations
described below were then performed on the single-ﬁbre
lysate on the following day.
Quantitative real-time PCR
Our quantitative real-time PCR assay for single muscle ﬁbres
was originally designed based upon the fact that the MTND1
gene is only rarely involved in large-scale rearrangements,
whereas the MTND4 gene is removed in the majority of
reported mtDNA deletions (38,46). Absolute quantiﬁcation
of mtDNA content was performed on the MyiQTM real-time
PCR detection system (Biorad, USA), with iQ SYBR Green
and primers pairs designed to amplify short fragments span-
ning MTND1 and MTND4 (23). The primer sequences for
the various real-time PCR templates used have been provided
in the online Supplementary Material (Table S2). The total
number of mtDNA molecules (total copy number) present in
muscle ﬁbre sections was determined from the MTND1 Ct
values, and the number of wild-type mtDNA molecules (wild-
type copy number) from the MTND4 Ct values, using the
linear regression equations generated by serial dilutions of
the relevant standards. Both assays were optimized and con-
ﬁrmed to be linear over an appropriate concentration range
by the standard curve method, and all single-ﬁbre lysates
were measured in triplicates. The mtDNA deletion level was
calculated with the 2
2DCt method from the obtained
MTND1–MTND4 DCt value.
Long-range PCR
Multiple mtDNA deletions in homogenate skeletal muscle
DNA was investigated with either southern blot and/or long-
range PCR (6,7). The detection of deleted mtDNA species in
single skeletal muscle ﬁbres was achieved using a previously
optimized two-step long-range PCR strategy (37). Two
rounds of PCR were required to achieve adequate ampliﬁca-
tion from the single-ﬁbre lysate, and the primer pairs were
speciﬁcally designed to allow the identiﬁcation of large-scale
rearrangements in the mutational hotspots along the major arc
of the mitochondrial genome (Supplementary Material,
Table S3). The Expand Long Template PCR SystemTM
(Roche, UK) was used with the following cycling procedures
for both the ﬁrst and second rounds of PCR: 3 min at 938C;
10 cycles of 938C for 30 s, 588C for 30 s, 688C for 12 min;
20 cycles of 938C for 30 s, 588C for 30 s, 688C for
12 min + 5 s per additional cycle; and a ﬁnal extension step
of 11 min at 688C. The PCR products were electrophoresed
in a 0.7% agarose gel containing ethidium bromide at 40 V
for 3 h, before being visualized under ultra-violet light.
Wild-type mtDNA ratio
For each patient, the mean wild-type mtDNA copy number
density for COX-positive muscle ﬁbres was determined by
averaging the values obtained for all Type I and II ﬁbres sep-
arately. To remove the variation among individuals, the wild-
type mtDNA ratios for COX-positive and COX-negative ﬁbres
were normalized to each patient’s mean wild-type mtDNA
copy number density. The wild-type mtDNA ratio for each
ﬁbre was calculated by dividing the copy number density for
that ﬁbre with the patient’s mean value for COX-positive
ﬁbres, either Type I or II.
In silico modelling
Our mathematical simulation of mtDNA replication is based
upon recessive loss-of-function mutations, with the total
amount of wild-type mtDNA being the primary determinant
of mitochondrial function (21,22). Our modelling equation
predicts that the wild-type mtDNA copy number (w) is a func-
tion of the mutation level (m) within a cell, and the mtDNA
proliferation parameter (a):
w =
1 − m
1 −( a − 1/a)m
The proliferation parameter (a) was determined from the wild-
type and mutant copy number data by a non-linear least
squares ﬁtting routine using the Levenberg–Marquardt algor-
ithm in Origin 7TM (Northampton, MA). The proliferation par-
ameter (a) represents the maximum proliferation that should
be observed when the mutation level approaches 100%. The
actual proliferation level observed will be smaller than the pre-
dicted a value.
Statistical analysis
Groups were compared using an independent sample t-test
with GraphPadTM v.4 statistical software (San Diego, CA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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